An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes

By Awada A.   Biganzoli L.   Cufer T.   Beex L.   Lohrisch C.   Batter V.   Hamilton A.   Nooij M.   Piccart M.  

European Journal of Cancer, Vol. 38, Iss. 6, 2002-01 ,pp. : 773-778

Elsevier

Access to resources Recommend Favorite

Beyond taxanes: the next generation of microtubule-targeting agents

By Cortes Javier  

Breast Cancer Research and Treatment, Vol. 133, Iss. 3, 2012-06 ,pp. : 821-830

Springer Publishing Company

Access to resources Recommend Favorite

The use of taxanes in early breast cancer

By Hudis C.  

EJC Supplements, Vol. 1, Iss. 7, 2003-10 ,pp. : 1-10

Elsevier

Access to resources Recommend Favorite

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

By Roché Henri  

Breast Cancer Research and Treatment, Vol. 125, Iss. 3, 2011-02 ,pp. : 755-765

Springer Publishing Company

Access to resources Recommend Favorite

Use and abuse of taxanes in the management of metastatic breast cancer

By Bernard-Marty C.   Cardoso F.   Piccart M.J.  

European Journal of Cancer, Vol. 39, Iss. 14, 2003-09 ,pp. : 1978-1989

Elsevier

Access to resources Recommend Favorite